News
01-08-2010, 06:05 AM
Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer...
More... (http://mnt.to/f/3w4J)
More... (http://mnt.to/f/3w4J)